AbCellera Biologics
ABCL
ABCL
114 hedge funds and large institutions have $1.99B invested in AbCellera Biologics in 2021 Q2 according to their latest regulatory filings, with 48 funds opening new positions, 50 increasing their positions, 8 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
6.61% more ownership
Funds ownership: 26.81% → 33.42% (+6.6%)
18% less capital invested
Capital invested by funds: $2.42B → $1.99B (-$431M)
Holders
114
Holding in Top 10
6
Calls
$32.1M
Puts
$22.5M
Top Buyers
| 1 | +$218M | |
| 2 | +$204M | |
| 3 | +$112M | |
| 4 |
GCA
Guardian Capital Advisors
Toronto,
Ontario, Canada
|
+$81.4M |
| 5 |
SM
SB Management
Abu Dhabi,
United Arab Emirates
|
+$44M |
Top Sellers
| 1 | -$648M | |
| 2 | -$43.5M | |
| 3 | -$23.9M | |
| 4 |
DFO
Duquesne Family Office
New York
|
-$22.4M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$17.8M |